whatsapp More From Our Partners Brave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgBiden received funds from top Russia lobbyist before Nord Stream 2 giveawaynypost.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgFlorida woman allegedly crashes children’s birthday party, rapes teennypost.comPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.orgA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comNative American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comSupermodel Anne Vyalitsyna claims income drop, pushes for child supportnypost.com KCS-content Tags: NULL Monday 28 March 2011 8:36 pm BAT aims for new markets as smuggling dents growth Share BRITISH American Tobacco (BAT) yesterday said a rise in cigarette smuggling and the wider decline in smoking across the developed world continue to press down on growth.Group sales by volume fell three per cent during 2010, though price rises more than offset the decline to deliver a five per cent revenue rise to £14.9bn, BAT said in its annual report. The firm said the “denormalisation” of smoking caused by increasing regulation is likely to continue hitting growth, though BAT’s market share has increased in several areas. A rise in illicit tobacco trade – now making up 12 per cent of sales by volume according to BAT – has also impacted on sales. However, the firm will restart a £750m share buyback this year as it is confident that the recovering global economy will bring in revenues.Paul Adams, who was chief executive until 28 February, made a total of £4.1m in 2010, taking home a £2.2m bonus alongside a £1.27m salary as well as other long-term benefits. New chief Nicandro Durante made £2.4m last year, when he served as chief operating officer. Outside the US, the firm is fighting more than 500 lawsuits linked to medical problems. Show Comments ▼ by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeMisterStoryWoman Files For Divorce After Seeing This Photo – Can You See Why?MisterStoryNight DailyHe Was The Smartest Man Who Ever Lived – But He Led A Miserable LifeNight DailyBetterBe20 Stunning Female AthletesBetterBeNews SharperGrab A Tissue Before You See Richard Simmons At 72News SharperThe Sports DropForgotten College Basketball Stars: Where Are They Now?The Sports DropUpbeat NewsThese 25 Celebrities Ruined Their Career in a Matter of MinutesUpbeat NewsMoneyPailShe Was A Star, Now She Works In ScottsdaleMoneyPailMagellan TimesThis Is Why The Roy Rogers Museum Has Been Closed For GoodMagellan TimesPeople TodayNewborn’s Strange Behavior Troubles Mom, 40 Years Later She Finds The Reason Behind ItPeople Today whatsapp
9.43pmSiraj brought into the attack now. The England batsman gets off the mark off the penultimate ball and Gill returns the fav IPL 2021: UAE suspends all flights from India till July 6th, will it impact IPL 2021 Phase 2 preparations? 11.07pmNagarkoti falls for 4; KKR 9 downChris Morris picks another wicket as Nagarkoti drags the ball back onto his stumps. KKR-108/9 after 19 overs; need more 87 from 6 balls11.02pmSaini into the 18th over of the innings. The match is in RCB’s pocket already. Virat Kohli and his men are giving their all in the fielding department. Not giving any freebies whatsoever. A referral for a catch off the final ball, Virat Kohli is the man involved, who dived to his front. But it gets turned down by the umpire. Five runs off the over.KKR-104/8 after 18 overs; need more 91 from 12 balls10.56pmSiraj into the 17th over of the innings. Tripathi smacks the third ball over the covers for a boundary. Finally, Tripathi departs, but it was not much of Siraj’s wicket, Morris completed a stunning diving catch. Four runs off the over. KKR-99/8 after 17 overs10.55pmSiraj puts the final nail in the coffinKKR’s last hope Rahul Tripathi falls for 16. Now it’s well and truly over for KKR. Just formalities left in the match now.10.51pmTripathi living on the edgeChahal returns for his final over and the 16th of the innings. A double off Chahal’s second delivery, followed by a single off the next. Yuzi flights the final ball and Tripathi hits it towards him, but it just falls short. Five runs off the over. KKR-95/7 after 16 overs; need more 100 from 24 balls Share on Facebook Tweet on Twitter IPL 2021 Phase 2: Aaron Finch slams RCB’s Maxwell and DC’s Stoinis for missing WI & BD tour, says IPL return will be ‘hard… IPL 2021 & T20 World Cup: BCCI top officials to meet in Mumbai this week for final call on T20 World Cup & dates… 10.18pmShubman Gill run out for 34Terrible mix up between the batsmen and it is Morgan, who has run himself out. Replays on the screen, but Morgan was well outside the crease. How costly will this be? Shubman Gill run out. FOW-60/310.13pmChahal into his second over. Finch drops a sitter at long on, Gill was the batsman in trouble. RCB take a referral for LBW against Eoin Morgan off the second ball, but its turned down by the third umpire. Just three runs off the over, great bowling by Yuzi. KKR-54/2 after 9 overs; need more 141 from 66 balls10.12pmRCB lose reviewUmpire gives not but De Villiers behind the stumps feels there was some wood involved. Kohli goes upstairs but both Ultra Edge and Ball tracking confirms that the onfield call was correct. RCB lose review.10.08pmSundar stikes; Nitish Rana falls for 9An angled delivery by Washington Sundar, coming at a decent pace and Rana goes down on his knees and tries to play it across the line. Rana, goes for the wild slog, but missed it completely. Super stuff from Sundar. FOW-51/2 after 8 overs IPL 2021 New updates: new Schedule, new dates, team, venue, live, squad, foreign players’ availability all you need to know TAGSIPL 2020IPL 2020 LiveIPL Live ScoreIPL Live streamingrcb v kkr scoreRCB vs KKRrcb vs kkr live scorercb vs kkr live streamingRCB Win by 82 runs SHARE Cricket IPL 2021: Bad news for IPL, Cricket Australia planning Tri-Series at the time of IPL 2021 Phase 2 Kolkata Knight Riders need 134 runs in the final 10 overs. Eoin Morgan and Dinesh Karthik are present at the crease. KKR-61/3 after 10 overs; need more 134 from 60 balls 10.47pmMorris back into his third over. Tripathi picks up a single off the first and Cummins returns the favour off the third. Cummins mistimes a slog and it went straight to Padikkal at long off. Four runs off the over. Kolkata Knight Riders need 105 runs in 30 balls. KKR-90/7 after 15 overs; need more 105 from 30 balls10.45pmCummins latest to departThe hard work is done for RCB. KKR has no more firepower left with the wicket of Pat Cummins. FOW-89/710.43pmUdana comes back and Dre Russ smacks him for a four and a six, before hitting it straight to Siraj at mid-on. The games is almost sealed here for RCB unless KKR can spring off some last moment surprise! KKR-86/6 after 14 overs; need more 109 from 36 balls10.41pmUdana strikes; Russell gone 16Big wicket for RCB! Excellent comeback from Udana. After going for a thrashing by Russell, he gets the breakthrough and ideally put the final nail in the coffin for KKR. Cricket Cricket Previous articleWWE RAW results October 13, 2020 LIVE streaming in India: How to watch it on AirtelTV, SonyLiv and JioTV, Check details hereNext articleIPL 2020 Purple Cap: Yuzvendra Chahal back in Top 5, Kagiso Rabada leading the highest wicket takers’ tally Kunal DhyaniSports Tech enthusiast, he reports on Sports Tech industry and writes on sports products. Cricket 10.24pmTop notch bowling from Chahal. Unlucky dismissal as the ball took an inside edge but RCB and Yuzi will happily take that. Dre Russ comes in just the 11th over and gets off the mark straight away; three runs off the over. KKR-64/4 after 11 overs; need more 131 from 54 balls10.21pmKKR lose skipper Dinesh KarthikKKR skipper Dinesh Karthik falls as Chahal castes his woodwork. KKR skipper is wrapped up by a tossed up delivery from Yuzvendra Chahal as he drags the ball back onto his stumps. He departs after scoring 1 from 2 balls. FOW-62/410.19pmWe reach the halfway mark! RELATED ARTICLESMORE FROM AUTHOR Maternity WeekA Letter From The Devil Written By A Possessed Nun In 1676 Has Been TranslatedMaternity Week|SponsoredSponsoredUndoBrake For ItThis NASCAR Wife Turns Heads Everywhere She GoesBrake For It|SponsoredSponsoredUndoYourBump15 Actors That Hollywood Banned For LifeYourBump|SponsoredSponsoredUndoDefinitionMost Embarrassing Mistakes Ever Made In HistoryDefinition|SponsoredSponsoredUndobonvoyaged.comTotal Jerks: These Stars Are Horrible People.bonvoyaged.com|SponsoredSponsoredUndoDaily FunnyFemale Athlete Fails You Can’t Look Away FromDaily Funny|SponsoredSponsoredUndo Cricket Cricket IPL Dates & Schedule: For sake of longer window for IPL, BCCI agrees to 2 more ICC events in next cycle: Report 10.40pm4,6,4Russel gets going. The Caribbean finally getting the momentum everyone was hoping for and it can be seen on the smiling faces in the KKR dugout. Can he turn around the fortunes for KKR tonight?10.34pmSecond Strategic Timeout takenExcellent from Morris; just 2 runs given at this stage of the game. KKR needs the big overs to happen. And we go into time out! KKR-71/5 after 13 overs; need more 124 from 42 deliveries.10.32pmRussell dropped on 1 by PadikkalA slower ball from Morris and Russell hits it hard in the air towards long-off. Devdutt Padikkal slides across and the ball pops out of his hands. Dre-Russ gets a life.10.29pm Sundar returns and removes Morgan. RCB spinners are on fire here. Tripathi, the new man in, cuts the ball fine but Yuzi puts in a dive to save the boundary. KKR-69/5 after 12 overs; need more 126 from 48 deliveries10.25pmEoin Morgan departs cheaplyEoin Morgan latest to depart as Washington Sundar picks up his 2nd wicket of the night. Morgan cuts but finds Udana at short third. Regulation catch for the Sri Lankan. KKR in real trouble now! FOW-64/5 Cricket IPL 2021: SRH’s Rashid Khan reveals how he plans bowling in matches IPL 2021 Phase 2: Franchises super-confident that BCCI will make all players available for IPL 2021 in UAE By Kunal Dhyani – October 12, 2020 CricketIndian premier leagueIndian premier league 2020 AB De Villiers gave a glimpse of his batting prowess with his fiery 33 ball 73 as KKR faltered to chase an uphill target of 195; succumbing by 82 runs in Sharjah. With the win, Virat Kohli’s men climbed to the third place in the IPL 2020.IPL 2020 RCB vs KKR Highlights and Complete Match Report: https://www.insidesport.co/ipl-2020-rcb-vs-kkr-highlights-de-villiers-fireworks-stun-kkr-rcb-clinch-massive-82-runs-win/ 10.04pmTight over from ChahalChahal comes in and a brilliant over from him; concedes just 3 runs. KKR-46/1 after 7 overs9.57pmEnd of Powerplay; Strategic Timeout takenSpin has been introduced in the form of Washington Sundar in the final over of the powerplay. Just four runs off the over, as expected from Sundar. KKR have managed 43 runs for the loss of one wicket at the end of powerplay as the umpire signal for timeout.KKR-43/1 after 6 overs; need more 152 from 84 balls9.54pmCostly from RCB; Gill hits a four and a sixSiraj into his second. Strays on the pads on the second ball and Nitish Rana just too good to miss out on that one, gets a boundary. Then Gill smashes him four two fours. 16 runs off the over. KKR- 39/1 after 5 overs; need more 156 from 90 balls9.48pmSaini comes in, Shubman gets off the mark, good rotation of strike here. Banton dabs the third ball in front of covers for a single. Saini finally removes Banton courtesy an inside edge that rattled the batsman’s stumps. KKR-23/1 after 4 overs; need more 172 from 96 balls9.47pmSaini gets the breakthroughBanton gone for 8. Saini steams in and he strikes. Clocks 148, the ball takes an inside edge and dislodges the stumps. FOW-23/1 Cricket IPL 2020 RCB vs KKR live score: RCB decimates KKR to secure a comprehensive 82 runs win Facebook Twitter by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeGrammarlyImprove Your Grammar With This Helpful Browser ExtensionGrammarlyUndoIPL 2020: Bad news for Sunrisers Hyderabad’s Jonny BairstowUndoIPL 2020 : Srikanth and fans slams MS Dhoni, says ‘wasted 15 Cr on Jadhav & Chawla’Undo11.20pmThat’s a wrap for tonight guys. See you again tomorrow with yet another high octane clash between SRH vs CSK11.12pmRCB wins by 82 runsA bowling masterclass from RCB after De Villiers’ fireworks as KKR crumble under pressure and failed to overturn their fortunes. RCB secures a comprehensive 82 runs win as KKR could only manage 112/9 after 20 overs. Indian Premier League: Big boost for BCCI, wins 6046 Crore case against Deccan Chargers IPL 2021 in UAE, Updates: finals, Schedule, point table, team, venue, live, squad, players’ availability all you need to know Cricket Cricket
Tropical Paradise Co Ltd (TPL.mu) listed on the Stock Exchange of Mauritius under the Tourism sector has released it’s 2014 interim results for the first quarter.For more information about Tropical Paradise Co Ltd (TPL.mu) reports, abridged reports, interim earnings results and earnings presentations, visit the Tropical Paradise Co Ltd (TPL.mu) company page on AfricanFinancials.Document: Tropical Paradise Co Ltd (TPL.mu) 2014 interim results for the first quarter.Company ProfileTropical Paradise Co Limited engages in the tourism and leisure sector where it operates hotels in Mauritius. Headquartered in Moka, Mauritius, the company operates the Labourdonnais Waterfront Hotel, Le Suffren Hotel & Marina, Hennessy Park Hotel, and Port Chambly Hotel. Tropical Paradise Co Limited (Ordinary) is listed on the Stock Exchange of Mauritius.
The following statement was issued by Black Workers for Justice, based in North Carolina.Again, we see the U.S. government trying to start another war as a diversion from the capitalist crisis that is causing great suffering among masses of working-class and poor people. The U.S. wars violate international laws and the U.S. Constitution, while attacking basic democratic and human rights to challenge the suffering and brutality carried out by the capitalist economy and the “State” (government).Trump got elected president on the racist promise of making America great again! Trump is intensifying the War on Black America — killing, maiming and jailing Black and Brown people, criminalizing immigrants and Muslims, and fostering regime change throughout the Americas.This attack on Syria is part of a U.S.-led global war that includes the War on Black America. Black people must oppose this war on Syria, all wars abroad and in the U.S. This war contributes to the economic and social crises.As our tax money is spent by the ruling 1% for war, there are more cuts to public services, schools, vocational education, jobs, health care, affordable housing, clearing up the environment, repairing the infrastructure, and supporting veterans that are disabled and mentally broken from fighting in these imperialist wars.The struggle for Black liberation must also be a struggle against imperialist wars. The European heads of the global capitalist system — the U.S., France and the U.K. are again deciding what part of the world they want to dominate and control for increasing their wealth, and positioning their militaries to dominate the world.We Say No to U.S. Led Racist and Imperialist Wars!FacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare this
Previous articleHoroscope: August 25, 2017Next articleStudent reported incident being investigated by Fort Worth police as sexual assault Branson Nelson RELATED ARTICLESMORE FROM AUTHOR ReddIt Iqbal leads women’s golf to fourth-place finish at Big 12 Tournament Branson Nelsonhttps://www.tcu360.com/author/branson-nelson/ TCU rowing program strengthens after facing COVID-19 setbacks A COVID-19 Charles Schwab Challenge Branson Nelsonhttps://www.tcu360.com/author/branson-nelson/ Branson Nelsonhttps://www.tcu360.com/author/branson-nelson/ Linkedin Women’s golf heads to Oklahoma for chance at first Big 12 title Photo courtesy of gofrogs.com Twitter Twitter + posts ReddIt Branson Nelson printAdrien Mörk is a new assistant coach of the men’s golf team.Mörk joins the staff after serving as an assistant coach at the University of Central Florida (UCF) for two years. Prior to his stint at UCF, Mörk coached for the French Golf Federation and served as the French Team Advisor at the 2015 European Team Championship in Sweden. He also coaches LPGA professional Perrine Delacour.“I’ve known the TCU program ever since Julien Brun played there,” Mörk said. “I know how good the program under Coach Montigel has been, so I couldn’t believe it when I got the phone call about the job. TCU is one of the top programs in the nation, and I feel like we can do something special in the next few years.”After winning the French High School Championship, Mörk played collegiately at McNeese State University from 2001-2004. He was a four-year team MVP and member of the All-Southland Conference team. He was the Louisiana Freshman of the Year in 2001 and advanced to the NCAA Regionals as an individual twice.As a professional, Mörk was the first player to shoot a 59 on the European Tour, an accomplishment he achieved in the second round at the 2006 Morocco Classic. The 59 followed an opening round of 63, giving him the lowest 36-hole score of any PGA Tour event at 122. In addition, Mörk won four times on the Alps Tour.“I’m really excited about the addition of Adrien Mörk to our golf program,” head coach Bill Montigel said. “He brings with him experience and success in recruiting, as well as national championship appearances. He is going to be a great fit for TCU and the guys will love him.”Mörk, his wife Sandrine and daughter Elin will be relocating to Fort Worth.“Everyone I know that lives in Fort Worth tells me how great it is,” Mörk said. “I can’t wait to be a part of the community and call Fort Worth and TCU home.” Facebook Branson Nelsonhttps://www.tcu360.com/author/branson-nelson/ Equestrian earns last seed in NCEA team bracket Branson is a junior journalism major from Fort Worth, Texas. He enjoys writing about all sports and plans to go to law school after graduation. Facebook Another series win lands TCU Baseball in the top 5, earns Sikes conference award Linkedin TCU baseball finds their biggest fan just by saying hello
Home Local News Business DAILY OIL PRICE: April 16 Snap Inc. to Participate in the Morgan Stanley Technology, Media & Telecom Conference 2021 Congressman Mike Conaway talks to the Odessa American on Jan. 7, 2018. Previous articleCouple charged with sexually abusing childNext articleHighway 285 traffic pattern to change admin RELATED ARTICLESMORE FROM AUTHOR Pinterest Rattler Midstream: 4Q Earnings Snapshot WhatsApp By admin – April 16, 2018 Crude Oil: 66.22 (-1.17)Nymex MTD AVG: 64.7350.Natural Gas: 2.752 (+.017).Gasoline: 2.0399 (-0.0255).Spreads: May/June (-.02) June/July (+.26).Plains WTI Posting: 63.00 (-.75). Twitter Octopus Energy U.S. to Discount Customers’ Bills by as Much as 90% Local NewsBusiness DAILY OIL PRICE: April 16 WhatsApp Facebook Foolproof Roasted Pork TenderloinVirgin Coco MojitoSlap Your Mama It’s So Delicious Southern Squash CasserolePowered By 10 Sec Mama’s Deviled Eggs NextStay Pinterest Facebook Twitter
LEXINGTON, Mass., Feb. 9, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in combination with ibrutinib, a BTK inhibitor, in patients with relapsed or refractory (R/R) hematologic malignancies. “In dosing the first patient in this Phase 1 study evaluating CA-4948 and ibrutinib, we are taking a highly anticipated step forward in bringing a potent oral therapeutic regimen to patients with relapsed or refractory hematologic malignancies,” said James Dentzer, President and Chief Executive Officer of Curis. “BTK inhibitors are an approved category of therapies for patients with various lymphatic cancers yet they only target one of the two main pathways activating NF-κB in B-cell malignancies. CA-4948 targets the other main NF-κB-activating pathway by shutting down signaling through the Myddosome. We have shown highly encouraging increased tumor-reducing activity when combining both covalent and non-covalent BTK inhibitors with CA-4948 in preclinical models.” Mr. Dentzer continued, “We observed single-agent activity in the non-Hodgkin’s lymphoma (NHL) monotherapy study, with the majority of patients treated at 300mg twice daily experiencing at least some reduction in tumor volume. We coordinated with our trial partners to amend the protocol of our existing study to include combination therapy starting at a previously demonstrated therapeutic dose. This will allow us to leverage the clinical sites and staff currently active in our monotherapy study and should save significant time and resources as we advance through the clinic.” “Given the profile CA-4948 has demonstrated in existing studies, it is a promising candidate for combination with a proven BTK inhibitor such as ibrutinib,” said Dr. Erel Joffe, M.D., Assistant Attending with the Lymphoma Service at Memorial Sloan Ketting Cancer Center and a lead investigator on the study. “We believe there may be important synergies given that IRAK4 controls the critical TLR pathway that is parallel and complementary to the BTK pathway and that both of these pathways are primary and independent oncogenic activators of NF-κB in lymphoma and leukemia. Effective dual targeting of both independent pathways that drive excessive B-cell proliferation via NF-κB could potentially provide significantly improved outcomes over either treatment in a monotherapy setting.” About the CA-4948+ibrutinib Phase 1 Combination Study The Phase 1 trial is a two-part, multicenter, open-label, dose escalation and expansion study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, clinical activity, and biomarker correlations of CA-4948 and ibrutinib patients with relapsed or refractory hematologic malignancies. Part 1 of the study is a dose escalation using a 3+3 design. Approximately 18 patients will be enrolled in Part 1 and will receive a starting dose of 200mg CA-4948 BID with subsequent escalation to 300mg BID, both of which have been observed to be safe and effective in the NHL monotherapy study, combined with ibrutinib doses appropriate for their respective NHL subtype. The primary endpoints of Part 1 will be safety and tolerability, maximum tolerated dose, and the recommended Phase 2 dose. Secondary objectives will be pharmacokinetics and preliminary efficacy. Exploratory objectives will include biomarker correlations, such as MYD88-L265P mutations and IRAK4 pathway and NFκB inhibition. Part 2 of the study will enroll patients across an expansion basket of four cohorts: marginal zone lymphoma (MZL), ABC-DLBCL, primary central nervous system lymphoma (PCNSL), and NHL with adaptive ibrutinib resistance. An interim futility analysis will be conducted after approximately 15-20 patients are enrolled in each cohort. Primary endpoints of Part 2 will be complete response or objective response rate and duration of response compared to historical controls. Secondary objectives will be safety and tolerability, progression-free survival, and population PK sampling for CA-4948. Exploratory objectives will include response correlation with biomarkers including MYD88-L265P or other genetic mutations, gene expressions, cell of origin, IRAK4 signaling, and resistance. About Curis, Inc. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 in patients with non-Hodgkin’s lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’ website at www.curis.com. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding any expectations of the potential for the Company’s proprietary drug candidate CA-4948, including the potential developments and benefits of CA-4948 in combination with BTK inhibitors such as ibrutinib, statements with respect to the timing of the Company’s studies, including enrollment and reporting of data, and the Company’s ability to advance and broaden its clinical programs. Forward-looking statements may contain the words “believes,” “expects,” “anticipates,” “plans,” “intends,” “seeks,” “estimates,” “assumes,” “will,” “may,” “could” or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. For example, Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis’s drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis’s drug candidates may not be replicated in later trials. There can be no guarantee that the collaboration agreements with Aurigene and ImmuNext will continue for their full terms, that Curis or its collaborators will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory authorities may determine to delay or restrict Genentech’s and/or Roche’s ability to continue to develop or commercialize Erivedge in BCC. Erivedge may not demonstrate sufficient or any activity to merit its further development in disease indications other than BCC. Competing drugs may be developed that are superior to Erivedge. In connection with its agreement with Oberland Capital, Curis faces risks relating to the transfer and encumbrance of certain royalty and royalty-related payments on commercial sales of Erivedge, including the risk that, in the event of a default by Curis or its wholly-owned subsidiary, Curis could lose all retained rights to future royalty and royalty-related payments, Curis could be required to repurchase such future royalty and royalty-related payments at a price that is a multiple of the payments it has received, and its ability to enter into future arrangements may be inhibited, all of which could have a material adverse effect on its business, financial condition and stock price. Curis will require substantial additional capital to fund its business. If it is not able to obtain sufficient funding, it will be forced to delay, reduce in scope or eliminate some of its research and development programs, including related clinical trials and operating expenses, potentially delaying the time to market for, or preventing the marketing of, any of its product candidates, which could adversely affect its business prospects and its ability to continue operations, and would have a negative impact on its financial condition and its ability to pursue its business strategies. Curis faces substantial competition. Curis also faces risks relating to potential adverse decisions made by the FDA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions, natural disasters, public health crises, political crises and other events outside of Curis’s control could significantly disrupt its operations or the operations of third parties on which Curis depends, and could adversely impact Curis’s operating results and its ability to raise capital. For example, the COVID-19 pandemic may result in closures of third-party facilities, impact enrollment in clinical trials or impact sales of Erivedge by Genentech and/or Roche. The extent to which the COVID-19 pandemic may impact Curis’s business or operating results is uncertain. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the caption “Risk Factors” in our most recent Form 10-K and Form 10-Q and the factors that are discussed in other filings that we periodically make with the Securities and Exchange Commission (“SEC”). In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis’s views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law. View original content to download multimedia: http://www.prnewswire.com/news-releases/curis-doses-first-patient-in-phase-1-study-of-ca-4948-in-combination-with-ibrutinib-in-patients-with-relapsed-or-refractory-hematologic-malignancies-301224625.html SOURCE Curis, Inc. Local NewsBusiness WhatsApp Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies Facebook Pinterest Pinterest By Digital AIM Web Support – February 9, 2021 TAGS Twitter Twitter WhatsApp Facebook Previous articleDaniel Kagan Promoted to President at Scientist.comNext articleArtisanal Self-Care Subscription Box Brand Little Slacks Announces Valentine’s Day Giveaway Digital AIM Web Support
Twitter Secretive Israeli nuclear facility undergoes major project Facebook Twitter WhatsApp Pinterest WhatsApp TAGS Local NewsWorld News By Digital AIM Web Support – February 25, 2021 Facebook Pinterest Previous articleADVA berichtet Rekordergebnis für Q4 2020 und veröffentlicht Gesamtjahreszahlen 2020Next articlePetersen helps Kings beat Blues 2-1 for 6th straight win Digital AIM Web Support
iStock/Thinkstock(NEW YORK) — Jeffrey Epstein, the disgraced millionaire who was facing federal sex trafficking charges, died by suicide early Saturday in his Lower Manhattan prison cell, three law enforcement officials told ABC News. Epstein hanged himself, law enforcement sources said. He was transported in cardiac arrest at 6:39 a.m. from Metropolitan Correctional Center to New York Downtown Hospital, according to sources.Epstein, 66, was set to stand trial next year for allegedly sexually abusing dozens of minor girls in New York and Florida.His death came less than three weeks after he was found unresponsive in his cell at the federal prison in Lower Manhattan, with marks on his neck that appeared to be self-inflicted, sources told ABC News.He had been on suicide watch since the July 23 incident.Epstein was arrested in July of this year for alleged sex trafficking of minor girls at his Upper East Side mansion and his home in Palm Beach, Florida. Some of the charges date back to the early 2000s.Epstein, 66, pleaded not guilty to the charges. He faced up to 45 years in prison if convicted.His alleged crimes were thrown back into the spotlight amid renewed scrutiny of the plea deal Epstein reached with the U.S. Attorney’s Office in Miami in 2007, led by then-U.S. Attorney Alexander Acosta. A non-prosecution agreement allowed Epstein, a hedge-fund manager, to plead guilty to two state charges and avoid federal charges for an allegedly broad pattern of similar sexual misconduct. He would serve just 13 months of an 18-month sentence in county jail in Florida.The alleged victims in that case told ABC News they were not made aware of the details of the plea agreement while it was being negotiated.The deal is currently under review by the Justice Department’s Office of Professional Responsibility. Acosta was serving as President Trump’s Labor Secretary amid the controversy over his role in the deal. He later resigned from that position.On Friday, a federal appellate court in New York unsealed around 2,000 pages of documents from a now-settled civil defamation case between Virginia Roberts Giuffre, an alleged Epstein victim, and British socialite Ghislaine Maxwell, a longtime Epstein associate.Giuffre accused Maxwell of recruiting her while she was working as a locker-room attendant at Mar-A-Lago in 2000 and bringing her to Epstein’s home for a massage. She claims that she eventually became a teen sex slave to Epstein, and a victim of sex trafficking, beginning at age 17, at the hands of both Epstein and Maxwell.The newly-unsealed documents showed that Giuffre alleged that Epstein and Maxwell directed her to have sex with, among others: Prince Andrew; criminal defense attorney Alan Dershowitz; former New Mexico governor Bill Richardson; former Senator George Mitchell; a well-known prime minster, who she wouldn’t name; and a foreign man who was introduced to her as a “prince.”Maxwell has consistently denied Giuffre’s claims.“Ghislaine Maxwell did not participate in, facilitate, manage or otherwise conspire to commit sex trafficking” as alleged by Giuffre, her attorney wrote in a 2016 court filing.Maxwell’s attorneys also contend in the newly unsealed court filings that Giuffre had “utterly failed” to substantiate her allegations that Maxwell facilitated her abuse. Giuffre’s claims about having been trafficked to other prominent men, Maxwell’s lawyers wrote, are “patently incredible.”Mitchell called the allegations “false.”“I have never met, spoken with or had any contact with Ms. Giuffre,” he said in a statement issued Friday. “In my contacts with Mr. Epstein I never observed or suspected any inappropriate conduct with underage girls. I only learned of his actions when they were reported in the media related to his prosecution in Florida. We have had no further contact.”Richardson also denied Giuffre’s claims.“These allegations and inferences are completely false. Governor Richardson has never even been contacted by any party regarding this lawsuit,” Maddy Mahony, a spokeswoman for Richardson, said in a statement. “To be clear, in Governor Richardson’s limited interactions with Mr. Epstein, he never saw him in the presence of young or underage girls. Governor Richardson has never been to Mr. Epstein’s residence in the Virgin Islands. Governor Richardson has never met Ms. Giuffre.”Giuffre’s allegations were never tested in court because the case was settled prior to trial.During a detention hearing in July, Epstein came face-to-face with two other accusers. Annie Farmer said she was 16 when Epstein had her sent to New Mexico where he was allegedly “inappropriate” with her. Courtney Wild told the judge she was 14 when Epstein allegedly sexually abused her in Palm Beach, Florida. Both women spoke in support of keeping Epstein locked up without bail.Epstein appeared to watch them address the judge, but his face showed no emotion.A federal judge later denied bail for Epstein, after deciding he was too great a flight risk to release from custody.Copyright © 2019, ABC Radio. All rights reserved.
Written by March 6, 2018 /Sports News – National Tom Brady: Patriots’ Super Bowl loss was ‘a great lesson’ for my children FacebookTwitterLinkedInEmailABC News(NEW YORK) — Tom Brady, after reflecting on the New England Patriots’ Super Bowl loss to the Philadelphia Eagles, says the defeat was an opportunity to teach his kids a valuable lesson.Brady’s three children — Vivian, 5, John, 10, and Benjamin, 8, — were visibly upset after watching his team lose.“That was the first time that I’d seen my kids really react in that way,” Brady, 40, said on his Facebook show Tom vs. Time.“You know, Benny was crying, Vivi was crying and they were sad for me and sad for the Patriots. But I just said to them, ‘Look you guys this is a great lesson. We don’t always win. We try our best and sometimes it doesn’t go the way we want.’”Copyright © 2018, ABC Radio. All rights reserved. Beau Lund